Table 3.
Summary of patient outcomes.
| # | Cohort (Dose, pfu) | Age | First and second interval (days) | Response during protocol | Time to progression (days) | Best response | Overall survival (months) | Final outcome | |
|---|---|---|---|---|---|---|---|---|---|
| After first surgery | After G47Δ therapy | ||||||||
| 1 | Cohort 1 (3.0 × 108) | 76 | 14 | PD | 7 | PD | 11.1 | 3.6 | Dead (tumor progression) |
| 2 | Cohort 1 (3.0 × 108) | 36 | 14 | PD | 27 | SD | 37.0 | 7.3 | Dead (tumor progression) |
| 3 | Cohort 1 (3.0 × 108) | 35 | 7 | SD | 382 | CR | 52.7 | 47.0 | Dead after improved (tumor progression) |
| 4 | Cohort 2 (1.0 × 109) | 60 | 9 | PD | 7 | PR | >156.5* | >143.9* | Stable* |
| 5 | Cohort 2 (1.0 × 109) | 61 | 12 | PD | 7 | SD | 31.5 | 7.2 | Dead (tumor progression) |
| 6 | Cohort 2 (1.0 × 109) | 55 | 7 | PD | 8 | PD | 23.2 | 15.2 | Dead (tumor progression) |
| 7 | Phase II (1.0 × 109) | 42 | 5 | PD | 23 | SD | 15.2 | 3.2 | Dead (tumor progression) |
| 8 | Phase II (1.0 × 109) | 42 | 13 | PD | 8 | PD | 19.2 | 6.4 | Dead (tumor progression) |
| 9 | Phase II (1.0 × 109) | 43 | 7 | SD | 95 | SD | 55.8 | 46.7 | Dead (tumor progression) |
| 10 | Phase II (1.0 × 109) | 50 | 6 | PD | 39 | SD | 29.4 | 6.9 | Dead (tumor progression) |
| 11 | Phase II (1.0 × 109) | 40 | 7 | PD | 7 | PD | 96.7 | 6.2 | Dead (tumor progression) |
| 12 | Phase II (1.0 × 109) | 62 | 7 | PD | 7 | SD | 30.5 | 11.6 | Dead (tumor progression) |
| 13 | Phase II (1.0 × 109) | 45 | 6 | PD | 34 | PD | 23.2 | 13.7 | Dead (tumor progression) |
*As of March 1, 2022.